{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":26,"n_cols":5,"rows_kept":26,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[10,2,10,3],[11,2,11,3],[12,2,12,3],[13,2,13,3],[15,2,15,3],[18,2,18,3],[19,2,19,3],[22,2,22,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910825936903321"]
[null,null,"Titolo",null,"Evaluation of drug candidates for preclinical development : pharmacokinetics, metabolism, pharmaceutics, and toxicology / / edited by Chao Han, Charles B. Davis, Binghe Wang"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, NJ, : John Wiley & Sons, c2010"]
[null,null,"ISBN",null,"9786612684906"]
[{"$nulls":4},"9781282684904"]
[{"$nulls":4},"1282684906"]
[{"$nulls":4},"9780470574898"]
[{"$nulls":4},"0470574895"]
[{"$nulls":4},"9780470574881"]
[{"$nulls":4},"0470574887"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (303 p.)"]
[null,null,"Collana",null,"Wiley series in drug discovery and development"]
[null,null,"Disciplina",null,"615.19"]
[{"$nulls":4},"615/.19"]
[null,null,"Soggetti",null,"Drug development"]
[{"$nulls":4},"Pharmacokinetics"]
[{"$nulls":4},"Drugs - Metabolism"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Includes index."]
[null,null,"Nota di contenuto",null,"EVALUATION OF DRUG CANDIDATES FOR PRECLINICAL DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; 1. INTRODUCTION; 2. PHARMACOKINETICS IN PRECLINICAL DRUG DEVELOPMENT: AN OVERVIEW; 3. THE ROLE OF MEMBRANE TRANSPORTERS IN DRUG DISPOSITION; 4. CYTOCHROME P450: STRUCTURE, FUNCTION, AND APPLICATION IN DRUG DISCOVERY AND DEVELOPMENT; 5. THE ROLE OF DRUG METABOLISM AND METABOLITE IDENTIFICATION IN DRUG DISCOVERY; 6. PROTEIN BINDING IN DRUG DISCOVERY AND DEVELOPMENT; 7. PREDICTION OF THE PHARMACOKINETICS IN HUMANS; 8. PHARMACEUTICS DEVELOPABILITY ASSESSMENT; 9. SAFETY ASSESSMENT IN DRUG DISCOVERY"]
[{"$nulls":4},"10. ASSESSMENT OF STRATEGIES UTILIZED TO MINIMIZE THE POTENTIAL FOR INDUCTION OF ACQUIRED LONG QT SYNDROME AND TORSADE DE POINTESINDEX"]
[null,null,null,"Sommario/riassunto","Emphasizes the integration of major areas of drug discovery and their "]
[{"$nulls":4},"importance in candidate evaluation  It is believed that selecting the \"\"right\"\" drug candidate for development is the key to success. In the last decade, pharmaceutical R&D departments have integrated pharmacokinetics and drug metabolism, pharmaceutics, and toxicology into early drug discovery to improve the assessment of potential drug compounds. Now, Evaluation of Drug Candidates for Preclinical Development provides a complete view and understanding of why absorption-distribution-metabolism-excretion-toxicology (AD"]